Senseonics (NYSE:SENS) shares remained relatively unmoved today on second-quarter results that beat the consensus sales forecast.
Shares of SENS rose 1% to 49¢ apiece in post-market trading after the earnings release on Wednesday, Aug. 6. They fell 8% to 45¢ apiece in mid-morning the next day.
The Germantown, Maryland-based long-term implantable CGM maker reported losses of $14.5 million. That equals 2¢ per share on sales of $6.65 million for the three months ended June 30, 2025.
Senseonics recorded a 28.5% bottom-line gain on a sales increase of 36.7%.
Losses per share landed equal with expectations on Wall Street. Sales, meanwhile, topped estimates as experts forecast $6.02 million in revenue.
Senseonics — one of the largest diabetes tech companies in the world — said its 79% new patient growth in the U.S. over the prior year drove its sales beat in the quarter.
Read more about Senseonics and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Highlights in the quarter included a deal to pair the company’s Eversense 365 year-long CGM implant with the Sequel Med Tech twiist automated insulin delivery system. The company also shared new development updates for its next-generation Gemini and Freedom Systems at ADA 2025.
“During the quarter we continued to drive a strong U.S. Eversense 365 launch focused on new patients, initiating enhanced DTC advertising in June to broaden actionable leads and enable acceleration in patients and revenue growth in the second half of the year,” said Tim Goodnow, president and CEO of Senseonics. “We advanced several other important strategic initiatives which drive uptake and advance our technology to position us for increased shareholder value while progressing the development of Gemini and Freedom.”
Senseonics maintained its full-year sales guidance for between $34 million and $38 million as its Eversense 365 rollout continues. The full-year 2025 financial outlook assumes approximately doubling the company’s global patient base during 2025.
The analysts’ take
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang maintain a “Hold” rating for Senseonics. They note catalysts like expanding coverage for the one-year sensor in the U.S., increased spending on direct-to-consumer marketing campaigns and sensor approval in Europe later this year.
They also note that Gemini remains on track for an pivotal study later this year, with a launch expected for the end of fiscal 2026. Gemini remains roughly one year behind Gemini. Both programs should get boosts from recent funding, including an investment from Abbott.
“With a large step-up needed later this year, [Senseonics] will need crisp commercial execution to meet expectations,” the analysts say.
